In September 2022, Roche transferred the sponsorship and management of supply, customer support, medical information, regulatory services, sales and marketing of Valcyte 50 mg/mL powder for oral solution to Pharmaco (Australia) Ltd in Australia. The current Consumer Medicine Information (CMI) and Product Information (PI) for Valcyte are available from the Therapeutic Goods Administration (TGA) website at: